ModPath Chat – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

ModPath Chat

Modern Pathology

Health & Fitness

Science

Frequency: 1 episode/17d. Total Eps: 92

ModPath Chat is the official podcast of Modern Pathology, the journal of the US and Canadian Academy of Pathology (USCAP). ModPath Chat features interviews with authors, opinion leaders and experts on the latest science, technology, and developments in the field of pathology. The monthly podcast series is hosted by Dr. George J. Netto, the Editor-in-Chief of Modern Pathology and the Simon Flexner Professor and Chair, Department of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine in Philadelphia

Read moreCollapse

Site

RSS

Apple

Data updated on 04/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇫🇷 France - Medicine
25/12/2024
#100
🇫🇷 France - Medicine
24/12/2024
#94
🇫🇷 France - Medicine
23/12/2024
#75
🇫🇷 France - Medicine
22/12/2024
#58
🇫🇷 France - Medicine
21/12/2024
#42
🇬🇧 Great Britain - Medicine
15/10/2024
#63
🇬🇧 Great Britain - Medicine
14/10/2024
#99

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.nature.com/articles/s41379-020-0578-0
2 shares
https://www.nature.com/articles/s41379-020-0638-5
2 shares
https://www.nature.com/articles/s41379-020-0544-x
1 share

https://urldefense.com/v3/__https:/doi.org/10.1038/s41379-021-00875-x__
1 share
https://doi.org/10.1038/s41379-021-00875-x
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 43%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Fumarate hydratase deficient renal cell carcinoma. Guido Martignoni and Anna Caliò

Friday, December 6, 2024 • Duration 18:22

Drs. Guido Martignoni and Anna Caliò from the University of Verona in Italy discuss their recent study on primary and metastatic fumarate hydratase (FH)-deficient renal cell carcinomas. Six metastatic tumors were histologically documented with high frequency of involvement of lymph nodes, liver and peritoneal cavity. Metastases were morphologically heterogeneous often differing from corresponding primary. Interestingly, some peritoneal metastases morphologically resembled a benign reactive mesothelial process or primary peritoneal mesothelioma, a pitfall that can be avoided by performing IHC panels that include PAX8 and FH. As for therapeutic predictors, significant PD-L1 labeling was found in 60% of primary renal tumors, whereas none of them carried pathogenetic EGFR mutations.

Read moreCollapse

Intraductal oncocytic papillary neoplasm, Claudio Luchini and Gaetano Paolini

Monday, November 18, 2024 • Duration 22:03

Dr. Claudio Luchini from the University of Verona and Dr. Gaetano Paolini from Brescia University Hospital in Italy discuss their systematic review article, published in Modern Pathology, on Intraductal oncocytic papillary neoplasm (IOPN) of the pancreas.

Read moreCollapse

Gastrointestinal Langerhans cell histiocytosis: New insights. Shaomin Hu and Yue Xue

Monday, October 28, 2024 • Duration 20:35

Our host discusses with Drs. Shaomin Hu from Cleveland Clinic and Yue Xue MD PhD, from Case Western Reserve in Cleveland Ohio, their multi-institutional study on gastrointestinal (GI) tract involvement by Langerhans cell histiocytosis (LCH). The authors highlight new insights from their large study showing that adult patients with multisystem LCH exhibit similar clinicopathologic features to those of pediatric patients. Adults with single-system LCH involving the GI tract have an excellent prognosis, whereas multisystem LCH occurring at any age carries an unfavorable prognosis. High-risk features of GI LCH include pediatric age, GI symptomatology, noncolorectal GI involvement, multifocal GI disease, nonpolypoid lesions, and infiltrative growth pattern.

Read moreCollapse

Opening the Black Box: Spatial Transcriptomics and the Relevance of Artificial Intelligence–Detected Prognostic Regions in High-Grade Serous Carcinoma. Anna Ray Laury et al

Thursday, October 10, 2024 • Duration 19:27

Our host discusses with Dr. Anna Laury, from the Department of Pathology, University of Helsinki, Finland, her team's study on the utilization of AI-guided spatial transcriptomic analysis to allow for the biological interpretation of morphologic features detected by AI algorithms when applied to WSI of standard H&E sections.

The authors previously trained an AI model to identify HGSC (high-grade serous carcinoma of the ovary) tumor regions that are highly associated with outcome status but are indistinguishable by conventional morphologic methods. In the here discussed study, Dr. Laury’s team applied spatially resolved transcriptomics to further profile the AI-identified tumor regions in 16 patients (8 per outcome group) and identify molecular features related to disease outcome in patients who underwent primary debulking surgery and platinum-based chemotherapy.

Read moreCollapse

Pathologist-Driven Reflex Somatic Tumor DDR Testing in Localized Prostate Cancer. Susan Prendeville and Shamini Selvarajah

Monday, September 9, 2024 • Duration 19:27

Our host discusses with Drs. Prendeville and Selvarajah, from the departments of Laboratory Medicine and Pathobiology at the University of Toronto, their recent study on Pathologist-Driven somatic testing for DNA Damage Repair (DDR) in prostate carcinoma (PCa).

516 FFPE samples from metastatic and localized high risk PCa cases including needle biopsies, TURP and RP specimens were tested using a custom NGS panel of 83 cancer predisposition genes encompassing 4 Homologous Recombination Repair (HRR) genes [BRCA1/2, ATM, PALB2] and 4 Mismatch Repair (MRR) [MLH1, MSH2, MSH6, PMS2]. 13.9% of patients had at least one AMP/ASCO/CAP tier I or tier II variant, whereas 21.5% patients had a tier III variant. Tier I/II variant(s) were identified in 27% of metastatic biopsy samples and 13% of primary samples.

The presence of a tier I/II variant was not significantly associated with the grade group (GG) or presence of intraductal (IDC-P) /cribriform carcinoma in the primary tumor and therefore may not be reliable to guide patient selection.

Read moreCollapse

Staging of Multiple NSCLC: Paradigm shift using molecular methods Natasha Rekhtman

Wednesday, August 21, 2024 • Duration 29:35

Non-small cell lung carcinomas (NSCLCs) commonly present as 2 or more separate tumors. They encompass separate primary lung carcinomas (SPLCs), representing independently arising tumors, or intrapulmonary metastases (IPMs), representing intrapulmonary spread of a single tumor. In this episode, Dr. Natasha Rekhtman, from Memorial Sloan Kettering Cancer Ctr, NY provides an update on the growing applications of genomic testing as a clinically relevant benchmark for determining clonal relationships in multiple NSCLCs. She discusses the limitations of morphology-based distinction of SPLCs vs IPMs and the pivotal insights that have emerged from studying multiple NSCLCs using genomic approaches as a gold standard.

Read moreCollapse

A Portrait of HER2- Low Invasive Lobular Carcinoma (ILC) of Breast. Lounes Djerroudi Anne Vincent-Salomon

Friday, August 2, 2024 • Duration 16:57

Our host discusses with Drs. Djerroudi and Vincent-Salomon, from the Institut Curie in Paris France, their recent study comparing HER2-negative invasive breast cancer of no special type (IBC-NST), with HER2-negative ILC. HER2-negative ILC had a higher frequency of HER2-zero cases (59.4% vs 53.7%) and a lower frequency of HER2-low (40.6% vs 46.3%). Clinicopathological features associated with HER2-low status (vs HER2-zero) in ILC were older age, postmenopausal status, non-classic ILC histological types, higher grade, and ER expression. While HER2-low ILC patients had a lower risk of local recurrence (vs HER2-zero) there was no association between HER2 status and either breast cancer specific survival or distant metastasis-free interval. ERBB3 was the unique mutated gene exclusively associated with HER2-low ILCs, albeit mutated at a low frequency (7.1%). The guests highlighted the potential therapeutic significance of their findings that HER2-low ILCs exhibit unique molecular and clinical attributes.

Read moreCollapse

Special Episode - Meet the Listeners

Friday, June 14, 2024 • Duration 22:04

A most exciting conversation with some of the many engaged listeners of our podcast around the globe. Our host is joined by Dr. Zeeshan Ansar from Karachi, Pakistan; Dr. Emilian Olteanu, from Timisoara, Romania; Dr. Sanam Loghavi from Houston, USA and Dr. Sanjay Mukhopadhyay, from Clevland, USA.

Read moreCollapse

Molecular Profiling of Sinonasal Olfactory Carcinoma with Lisa Rooper, MD

Friday, May 31, 2024 • Duration 19:14

In this episode, our host and Dr. Lisa Rooper from Johns Hopkins University, on behalf of her group of esteemed coauthors, discuss their recent study on the molecular characteristics of “Olfactory Carcinoma.” Targeted molecular profiling of 23 cases of the rare sinonasal tumor was performed to help clarify their pathogenesis and classification. The authors found recurrent Wnt pathway and ARID1A alterations, suggesting that sinonasal neuroendocrine and epithelial tumors may be best regarded as a histologic and molecular spectrum.

Read moreCollapse

Liver Pathology in the Molecular Era: A Conversation with the USCAP 2024 Long Course Codirectors

Wednesday, May 22, 2024 • Duration 19:14

Integration of molecular analyses in routine diagnostics is the new practice paradigm of surgical pathology practice. The 2024 USCAP Long Course led by Dr. John Hart from the University of Chicago and Daniela Allende of Cleveland Clinic focuses on hepatic neoplasms and medical diseases where there are opportunities for ancillary molecular testing to refine the diagnosis and provide clinically relevant prognostic information. In this episode, the guests offer a preview of the long course sessions encompassing the utility of germline testing to identify liver disease risk alleles and the exciting potential of emerging technologies.

Read moreCollapse

ModPath Chat – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

ModPath Chat – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Nature24

DOI Foundation2

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Nature24

DOI Foundation2

Apple Podcasts

Spotify